Hi goarmy2020, Here is another one that came out this morning
Good Morning,
I hope you got a good nights rest as the opening bell is around the
corner and we are sitting on the launching pad with NPHC.
Lets recap for a moment... NPHC finished of 2016 with $168K in Rev's,
has two products in the market place which use Cobra Venom as the
key ingredient for pain management for multiple disorders not just in
humans but in Pet's to... a massive market.
Keep in mind, as you read this, the offer on NPHC is climbing already
pre market above Friday's levels. The word is out, people are watching
and given the share structure, FDA Orphan Status granted on a Patented
product, all packaged in a subby chart with massive up side potential
can you really be surprised if this chart takes off?
NPHC is one of a few sub penny's with a ratings.
NPHC specializes in pharma products and technology for:
Neurological Disorders
Cancer
Autoimmune Disorders
Infectious diseases
Multiple Sclerosis
Human Immunodeficiency Virus (HIV)
Adrenomyeloneurapathy (AMN)
Pain Management.
Currently, Nutra Pharma offers several Pharma products for sale for the
treatment of pain: Nyloxin®, the first over-the-counter (OTC) pain reliever
clinically proven to treat moderate to severe (Stage 2) chronic pain, and
Nyloxin Extra Strength, the only non-narcotic and non-addictive
treatment for severe (Stage 3) pain.
Nyloxin® is protected under patent #7,902,152, Use of cobratoxin as an
analgesic.
In December of 2014, the Company launched Pet Pain-Away - the first
OTC product to treat pain in companion animals without side effects.
The moment you put Patent and Pharma in the same sentence, investors
tend to flock rapidly to grab their positions.
Nutra Pharma has completed pre-clinical and animal models for their MS
and HIV applications and are preparing to move into pivotal Phase II
trials.
Nutra Pharma's MS drug was recently granted Orphan Status by
the FDA for the treatment of Pediatric Multiple Sclerosis
So....This is where it gets interesting...
NPHC uses Cobra Venom for treatment
of pain... NBC News Miami aired an
interview with CEO Rick Deitsch on this
ancient method that is making a
modern comeback.
At the end of 2016, NPHC CEO issued a letter to share holders which
clearly paints the picture of why their chart is in a bullish formation:
RSI - Right on the oversold line, VERY BULLISH
Price - Under support line, 52Week LOWS. Bullish
MACD - Far under zero line, in a bullish set up.
Acc/Dist - Trending up from bottom levels. Bullish
I hope now you are starting to get a better picture of why NPHC is
on high alert, sitting on 52Week lows, packing fundamentals that
could rival some big board pharma companies and could become
a multi-week monster.
Start your research on NPHC right away and enjoy.
Sincerely,
AST
DISCLAIMER
